3-hydroxy-3-methylglutaryl-CoA reductase

Overview

3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase, commonly abbreviated HMGCR) is a key enzyme in the mevalonate pathway and the principal rate-limiting step in cholesterol biosynthesis. It catalyzes the conversion of 3-hydroxy-3-methylglutaryl-CoA to mevalonate, making it a central regulator of cellular cholesterol production and broader lipid metabolism. Because of this role, HMGCR is one of the most clinically important metabolic enzymes in medicine and pharmacology.

HMGCR is also the canonical molecular target of statins, which inhibit the enzyme to lower cholesterol and reduce cardiovascular risk. Beyond lipid lowering, HMGCR has been investigated in contexts involving glucose and lipid metabolism, cancer biology, inflammatory signaling, and disease risk modulation. Recent studies have also explored HMGCR as a target in computational drug discovery, Mendelian randomization analyses, and mechanistic work on metabolic reprogramming, reflecting its broad biomedical relevance.

Role in Recent Research

Recent publications have continued to position HMGCR as a central node in cholesterol and lipid biology, while also extending its relevance to cancer, nephropathy, neuropathic pain, and metabolic engineering.

In metabolic engineering research, a class II HMG-CoA reductase from Delftia acidovorans was evolved toward improved NADPH utilization. The study used a carbon co-feeding strategy to expand redox-balance growth coupling techniques, and HMGCR served as the enzyme target for directed evolution. The reported outcome was enrichment of variants with improved NADPH-dependent activity, highlighting how HMGCR can be engineered to alter cofactor preference in microbial systems.

In prostate cancer research, single-cell RNA-seq and AI/machine learning were used to characterize lipid metabolic reprogramming. HMGCR was identified, together with MVK, STARD3, FADS1, and APOE, as a central regulator of fatty acid and cholesterol metabolism. This supports the view that HMGCR is part of a broader lipid-metabolic hub in tumor biology, where cholesterol synthesis and related pathways may contribute to cancer cell adaptation.

In diabetic nephropathy research, molecular docking was used to evaluate salvianolic acid A against multiple targets, including HMGCR. The study reported strong binding affinities to HMGCR and several other proteins such as FYN, AKR1B1, TNF, GALK1, MAP2K2, SCN4A, and ITGA5. This suggests that HMGCR may be one of several candidate targets through which salvianolic acid A could exert multi-target effects in diabetic nephropathy.

A separate integrated computational and structural study of Prunus bokharensis-derived β-glucan identified HMGCR, along with NPC1L1, NR1H3, ESR2, and SHBG, as essential network elements. In that work, HMGCR appeared within a lipid-hormone axis framework relevant to immunomodulation, antimelanoma activity, and erythroprotection. The study used network pharmacology, docking, and molecular dynamics simulations to support multi-target interactions, again reinforcing HMGCR’s role in cholesterol-related signaling networks.

Genetic research has also examined HMGCR in relation to cholelithiasis. One study focused on HMGCR-related single-nucleotide polymorphisms and suggested that statins may exert effects beyond lipid lowering. In this context, HMGCR was treated as the target of statins to simulate statin effects, linking genetic variation in the enzyme to gallstone disease risk and potential pleiotropic actions of statin therapy.

In neuropathic pain research, Mendelian randomization was used to evaluate whether genetically proxied inhibition of HMGCR, PCSK9, and NPC1L1 is associated with diabetic peripheral neuropathy, trigeminal neuralgia, and postherpetic neuralgia. This design aimed to infer whether lifelong reduction of HMGCR activity might influence pain-related outcomes, extending HMGCR research beyond lipid disorders into neurological phenotypes.

Finally, in colorectal cancer research, Atorvastatin was tested in combination with SREBP2 inhibitors in two-dimensional and three-dimensional culture models. Since statins inhibit HMGCR, the study framed HMGCR inhibition as part of an anti-cancer strategy and reported that statins have been described as exerting anti-cancer effects. This work reflects ongoing interest in HMGCR as a therapeutic target in oncology, particularly in combination approaches that modulate cholesterol-regulatory feedback pathways.

Across these studies, HMGCR emerges as a target at the intersection of cholesterol biosynthesis, lipid metabolic reprogramming, statin pharmacology, and disease-specific pathway modulation. The recent literature spans microbial enzyme engineering, cancer metabolism, nephropathy, gallstone genetics, neuropathic pain epidemiology, and combination anti-cancer therapy.

Key Publications

NEWJul Expanding the scope of redox-balance growth coupling techniques with a carbon co-feeding strategy. (Metabolic engineering, 2026, PMID 42155845): "We then used this selection to evolve a class II HMG-CoA reductase (HMGR) from Delftia acidovorans toward NADPH utilization, enriching variants with improved NADPH-dependent activity."
NEWJun Machine Learning-Based single-cell characterization of lipid metabolic reprogramming in prostate cancer. (Computers in biology and medicine, 2026, PMID 42361409): "Key hub genes HMGCR, MVK, STARD3, FADS1, and APOE were identified as central regulators of fatty acid and cholesterol metabolism."
Jun Elucidating the therapeutic targets and multi-target mechanisms of salvianolic acid A for diabetic nephropathy. (Mammalian genome : official journal of the International Mammalian Genome Society, 2026, PMID 42342966): "Molecular docking demonstrated strong binding affinities of salvianolic acid A to the domains of FYN, AKR1B1, TNF, GALK1, HMGCR, MAP2K2, SCN4A, and ITGA5."
Jun Integrated computational and structural understanding of Prunus bokharensis-derived β-Glucan: HRMS, network pharmacology, docking, and MD simulations to discover multi-target interactions for immunomodulation, antimelanoma lipid-hormone axis modulation, and erythroprotection. (Computers in biology and medicine, 2026, PMID 42054915): "...identified NPC1L1 and HMGCR and NR1H3 and ESR2 and SHBG as essential network elements."
May HMGCR-related SNPs and cholelithiasis: statins may exert effects beyond lipid-lowering. (Postgraduate medical journal, 2026, PMID 41378867): "...the target of statins, HMGCR, to simulate the effect of statins..."
May Statin Use and Neuropathic Pain: Evidence from NHANES and Mendelian Randomization Analyses. (Molecular neurobiology, 2026, PMID 42081017): "evaluate whether genetically proxied inhibition of HMGCR, PCSK9, and NPC1L1 is associated with DPN, trigeminal neuralgia (TN), and postherpetic neuralgia (PHN)."
May Evaluation of Combined Treatment With Atorvastatin and SREBP2 Inhibitors Against Colorectal Cancer Cells Under Two-dimensional and Three-dimensional Culture Models. (Anticancer research, 2026, PMID 42049373): "Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, have been reported to exert anti-cancer effects."